Today: 17.Oct.2017
EANM prostate cancer (European Association of Nuclear Medicine) Austria Europe
21.Jul.2017
Rate this item
(0 votes)

European Association of Nuclear Medicine: Prostate cancer patients who are resistant to hormone treatment used to have a poor prognosis. Until recently, the diagnostic and therapeutic possibilities had been limited, but now innovative developments in nuclear medicine imaging and therapy open up promising pathways. Novel substances used with PET/CT (positron-emission tomography combined with computed tomography) not only allow for better diagnosis but also offer treatment options where other therapies have failed.

Read 111 times Last modified on Thursday, 12 October 2017 12:58

Newsletter Subscription

  • Latest
  • Popular
  • Michael Shellenberger, Environmental Progress: Since the Fukushima…
  • Clinton Crackel, Co-founder and Co-chairman Nuclear Fuels…
  • Clinton Crackel, Co-founder and Co-chairman Nuclear Fuels…
  • Walter Horsting, Principal Business Development International: The…
  • Paul Driessen, senior policy analyst for the…
  • Clinton Crackel, Co-founder and Co-chairman Nuclear Fuels…
  • Walter Horsting, Principal Business Development International: The…
  • Michael Shellenberger, Environmental Progress: Since the Fukushima…